Kintara Therapeutics (NASDAQ: KTRA) shares are trading higher on Monday after Aegis Capital initiated coverage on the stock with a Buy rating and announced a price target of $6 per share.
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors.
The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.
Kintara Therapeutics shares were trading up 7.50% at $1.72 during the time of publication Monday. The stock has a 52-week high of $1.95 and a 52-week low of 38 cents.
Latest Ratings for KTRA
|Sep 2020||Aegis Capital||Initiates Coverage On||Buy|
View More Analyst Ratings for KTRA
View the Latest Analyst Ratings
See more from Benzinga
- Why Inhibrx's Stock Is Trading Higher Today
- Why Sutro Biopharma's Stock Is Trading Higher Today
- Why Zynex's Stock Is Trading Higher Today
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.